Published in J Herb Pharmacother on January 01, 2004
A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther (2008) 1.46
Herb-drug interactions: an overview of systematic reviews. Br J Clin Pharmacol (2013) 1.06
Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci (2011) 0.93
A randomized, double blind, placebo controlled, cross over study to evaluate the analgesic activity of Boswellia serrata in healthy volunteers using mechanical pain model. Indian J Pharmacol (2014) 0.88
A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. Int J Med Sci (2011) 0.86
Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci (2010) 0.86
Triterpenoid resinous metabolites from the genus Boswellia: pharmacological activities and potential species-identifying properties. Chem Cent J (2013) 0.84
Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev (2014) 0.83
Effect of Boswellia papyrifera on cognitive impairment in multiple sclerosis. Iran J Neurol (2014) 0.78
Frankincense and myrrh suppress inflammation via regulation of the metabolic profiling and the MAPK signaling pathway. Sci Rep (2015) 0.77
Boswellic acid activity against glioblastoma stem-like cells. Oncol Lett (2016) 0.75
Wound healing potentials of Thevetia peruviana: Antioxidants and inflammatory markers criteria. J Tradit Complement Med (2017) 0.75
Effect of Boswellia serrata Resin Supplementation on Basic Chemical and Mineral Element Composition in the Muscles and Liver of Broiler Chickens. Biol Trace Elem Res (2017) 0.75
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med (2006) 6.34
Against diagnosis. Ann Intern Med (2008) 3.69
Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health (2008) 3.68
Researching complementary and alternative treatments--the gatekeepers are not at home. BMC Med Res Methodol (2007) 2.96
Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol (2007) 2.36
Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med (2002) 2.29
Therapeutic applications of fenugreek. Altern Med Rev (2003) 2.12
Whole systems research: a discipline for studying complementary and alternative medicine. Altern Ther Health Med (2003) 2.05
Complementary and alternative medicine in undergraduate medical education. Associate deans' perspectives. Can Fam Physician (2004) 2.03
Complementary and alternative medicine whole systems research: beyond identification of inadequacies of the RCT. Complement Ther Med (2005) 1.97
Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin (2012) 1.94
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care (2012) 1.84
U.S. and Canadian pharmacists' attitudes, knowledge, and professional practice behaviors toward dietary supplements: a systematic review. BMC Complement Altern Med (2006) 1.71
Integrating complementary and alternative medicine into academic medical centers: experience and perceptions of nine leading centers in North America. BMC Health Serv Res (2005) 1.71
Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm (2003) 1.70
A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. J Palliat Med (2010) 1.64
Interprofessional collaboration within Canadian integrative healthcare clinics: Key components. Soc Sci Med (2009) 1.53
How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy. Eur Urol (2011) 1.50
Abrogation of the retinoblastoma tumor suppressor checkpoint during keratinocyte immortalization is not sufficient for induction of centrosome-mediated genomic instability. Cancer Res (2003) 1.48
Improving the quality of reporting of randomized controlled trials evaluating herbal interventions: implementing the CONSORT statement [corrected]. Explore (NY) (2006) 1.47
Reliability of adverse symptom event reporting by clinicians. Qual Life Res (2011) 1.45
Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early stage endometrial cancer. Ann Surg Oncol (2014) 1.45
Superstition but not distrust in the medical system predicts the use of complementary and alternative medicine in a group of patients with acute leukemia. Leuk Lymphoma (2008) 1.42
Supporting clinical practice decisions with real-time patient-reported outcomes. J Clin Oncol (2011) 1.41
The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. Pain Med (2010) 1.40
Targeted drugs for metastatic renal cell carcinoma. Lancet (2007) 1.36
Canadian pharmacy students' knowledge of herbal medicine. Am J Pharm Educ (2008) 1.35
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. J Clin Oncol (2013) 1.34
Patients' responsibility to participate in decision making and research. JAMA (2013) 1.32
Quality of reporting of randomized controlled trials of herbal medicine interventions. Am J Med (2006) 1.31
Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literature. BMC Med Res Methodol (2012) 1.29
Moving forward? Complementary and alternative practitioners seeking self-regulation. Sociol Health Illn (2004) 1.27
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer (2010) 1.25
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res (2010) 1.22
Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst (2011) 1.21
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res (2013) 1.21
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer (2013) 1.21
How far can complementary and alternative medicine go? The case of chiropractic and homeopathy. Soc Sci Med (2006) 1.21
Recommendations for reporting randomized controlled trials of herbal interventions: Explanation and elaboration. J Clin Epidemiol (2006) 1.20
Acupuncture as a promising treatment for below-level central neuropathic pain: a retrospective study. J Spinal Cord Med (2003) 1.16
Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health (2012) 1.15
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2013) 1.15
The use of CAM by women suffering from nausea and vomiting during pregnancy. BMC Complement Altern Med (2002) 1.15
Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance. Drug Saf (2013) 1.13
American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol (2012) 1.12
Integrative health care: how can we determine whether patients benefit? J Altern Complement Med (2005) 1.12
A survey of attitudes towards paediatric vaccinations amongst Canadian naturopathic students. Vaccine (2004) 1.10
St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics (2003) 1.10
The role of the state in the social inclusion of complementary and alternative medical occupations. Complement Ther Med (2004) 1.08
Addressing the emergence of pediatric vaccination concerns: recommendations from a Canadian policy analysis. Can J Public Health (2006) 1.08
Mothers' beliefs about analgesia during childhood immunization. Paediatr Child Health (2010) 1.07
The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors. BMC Health Serv Res (2006) 1.06
Core competencies in natural health products for Canadian pharmacy students. Am J Pharm Educ (2010) 1.03
Return to work in low-income Latina and non-Latina white breast cancer survivors: a 3-year longitudinal study. Cancer (2011) 1.02
Designing a framework for the delivery of collaborative musculoskeletal care involving chiropractors and physicians in community-based primary care. J Interprof Care (2010) 1.02
Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells. Breast Cancer Res Treat (2010) 1.01
Multischool, international survey of medical students' attitudes toward "holism". Acad Med (2005) 1.01
Interprofessional collaboration within integrative healthcare clinics through the lens of the relationship-centered care model. J Interprof Care (2010) 1.01
Pharmacists' participation in research: a case of trying to find the time. Int J Pharm Pract (2010) 0.98
Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Med Inform Decis Mak (2010) 0.98
Consumers of natural health products: natural-born pharmacovigilantes? BMC Complement Altern Med (2010) 0.98
Responses of established healthcare to the professionalization of complementary and alternative medicine in Ontario. Soc Sci Med (2004) 0.97
CAM in Canada: places, practices, research. Complement Ther Clin Pract (2005) 0.96
Roles and responsibilities of pharmacists with respect to natural health products: key informant interviews. Res Social Adm Pharm (2009) 0.95
Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). J Pain Symptom Manage (2010) 0.94
Characteristics of pediatric and adolescent patients attending a naturopathic college clinic in Canada. Pediatrics (2005) 0.94
Practitioners' validation of framework of team-oriented practice models in integrative health care: a mixed methods study. BMC Health Serv Res (2010) 0.94
Pharmacists and Natural Health Products: A systematic analysis of professional responsibilities in Canada. Pharm Pract (Granada) (2008) 0.93
The status of complementary therapy services in Canadian palliative care settings. Support Care Cancer (2007) 0.92
The king's foot of patient-reported outcomes: current practices and new developments for the measurement of change. Qual Life Res (2011) 0.92
Ontario family physician readiness to collaborate with community pharmacists on drug therapy management. Res Social Adm Pharm (2010) 0.92
A review of dietary supplement-induced renal dysfunction. Clin J Am Soc Nephrol (2007) 0.92
Evidence-based systematic review of dandelion (Taraxacum officinale) by natural standard research collaboration. J Herb Pharmacother (2005) 0.91
Elevated endogenous expression of the dominant negative basic helix-loop-helix protein ID1 correlates with significant centrosome abnormalities in human tumor cells. BMC Cell Biol (2010) 0.91
Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med (2005) 0.90
Women's decision-making about their health care: views over the life cycle. Patient Educ Couns (2002) 0.90
Herbal remedy clinical trials in the media: a comparison with the coverage of conventional pharmaceuticals. BMC Med (2008) 0.88
Evidence-based systematic review of saw palmetto by the Natural Standard Research Collaboration. J Soc Integr Oncol (2006) 0.88
Trial of Essiac to ascertain its effect in women with breast cancer (TEA-BC). J Altern Complement Med (2006) 0.88
Fenugreek (Trigonella foenum-graecum L. Leguminosae): an evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother (2007) 0.88
Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study. Eur J Endocrinol (2012) 0.88
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage (2011) 0.88
Malignant tumors of the oral cavity and oropharynx: clinical, pathologic, and radiologic evaluation. Neuroimaging Clin N Am (2003) 0.87
Inhibition of human cytochrome p450 metabolism by blended herbal products and vitamins. J Pharm Pharm Sci (2011) 0.87
Kava monograph: a clinical decision support tool. J Herb Pharmacother (2002) 0.87